Keep your BE program in the Kingdom, on schedule, under your control.
The BE partner who gives pharmaceutical companies faster access, local execution, regulatory confidence, and lower overall project risk and cost.
Credentials
- SFDA registered
- ICH-GCP compliant
- GCC compliant
- Aligned with Vision 2030
Keeping your generic development programme closer, simpler, and more efficient.
Why your program stays with NAMA BIO-Center?
Until now, Saudi manufacturers proving genieric bioequivalence often had to conduct studies abroad—adding travel and logistical costs, longer timelines, and greater operational risk from managing studies across borders.
Local
Screening, dosing, sampling and reporting all happen inside the Kingdom.
Regulatory
SFDA-registered and ICH-GCP, built around the pathway your dossier has to pass.
Speed
No shipping lanes and no foreign queue, so the timeline shortens at both ends.
Convenience
One contract, one team, one building — and a site you can visit this month.
Quality
GLP bioanalysis with Eurofins, in a purpose-built unit with a standing QA function.
Long-term partnership
We are building Saudi bioequivalence capacity for the long run, not selling study slots.
End-to-end services in our units
Clinical conduct, bioanalysis and training — so a study never leaves our units until its report is ready.
Bioequivalence Study ServicesProtocol to clinical report, designed, dosed, sampled and monitored in our own unit.Read more
Bioanalytical ServicesLC-MS/MS method development, validation and sample analysis to GLP, with Eurofins.With Eurofins — bioanalytical partnerRead more
Training & Capacity BuildingGCP, bioequivalence and regulatory training for sponsors, CROs and investigators.Read more
The facility in numbers
- 42+Clinical bedsPurpose-built participant ward
- 1000+m²Dedicated units for bioequivalenceDedicated basement BE floor
- 15+YearsExperienced clinical research team
Inside our clinical unit
A two-floor clinical unit built with CARE Medical for one purpose with Eurofins as bioanalytical partner.
Localizing pharmaceutical R&D is national policy. This is what it looks like built.
NAMA Bio directly supports Vision 2030 by localizing pharmaceutical R&D and research, reducing dependency on foreign research infrastructure, and enabling the growth of a competitive, innovation-driven life sciences sector in Saudi Arabia.
Ready to run your BE programme in the Kingdom?
Tell us the molecule, the dosage form and the timeline you are working to. We will come back with a study design and a schedule.